Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
Strober B, Asahina A, Mrowietz U, Lebwohl M, Foley P, Langley R, Barker J, Cioffi C, Cross N, Wang M, Paul C. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal Of Cutaneous Medicine 2021, 5: s52. DOI: 10.25251/skin.5.supp.52.Peer-Reviewed Original Research